Trials / Completed
CompletedNCT03634995
An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants
A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunologic Effects of BMS-986256, and a Relative Bioavailability Study in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects of the experimental medication BMS-986256 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986256 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2018-08-14
- Primary completion
- 2019-10-09
- Completion
- 2019-10-09
- First posted
- 2018-08-17
- Last updated
- 2020-06-16
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03634995. Inclusion in this directory is not an endorsement.